1. Introduction
===============

Low back pain (LBP) is the second most common disorder that affects adult population.^\[[@R1]--[@R4]\]^ It has been reported that its prevalence rate is 84% in a lifetime for a general population.^\[[@R5],[@R6]\]^ Many factors are reported to contribute to the LBP, such as nerves, bones, musculatures, fascia, joints, and any other conditions that may result in this disorder.^\[[@R7]--[@R10]\]^ If this condition cannot be treated effectively, it may result in very poor quality of life in patients who experienced LBP.^\[[@R11]--[@R13]\]^

Treatment approaches for this condition mainly include pharmacological and non-pharmacological treatments.^\[[@R14],[@R15]\]^ However, pharmacological treatments often involve limited efficacy and most importantly bring a variety of adverse events for patients.^\[[@R16],[@R17]\]^ Thus, current treatment guidelines for this condition mainly focus on the non-pharmacological treatments, as recommended by The Guidelines for Chronic Back Pain of the American College of Medicine, published in 2017.^\[[@R18]\]^

Extracorporeal shock wave (EPSW) is reported to treat LBP effectively with fewer adverse events.^\[[@R19],[@R20]\]^ However, there is limited evidence concerning its effectiveness and safety of EPSW for patients with LBP. Thus, this protocol of systematic review aims to determine the effectiveness and safety of EPSW for LBP, providing a scientific evidence for clinical decision.

2. Methods and analysis
=======================

2.1. Eligibility criteria for study selection
---------------------------------------------

### 2.1.1. Types of study

Only randomized controlled trials (RCTs) and case-control studies assessing the effectiveness and safety of EPSW for LBP will be included. We will exclude any other studies, such as nonclinical trials, case reports, and case series.

### 2.1.2. Types of participant

Patients with clinically diagnosed of LBP will be included without restrictions of race, sex, and age.

### 2.1.3. Types of intervention

Any included studies for evaluating the effectiveness and safety of EPSW only for patients with LBP will be included. Additionally, the studies using the EPSW plus other therapies will be excluded. The control interventions can be the placebo, medications, and so on, except the EPSW.

### 2.1.4. Types of outcome measurement

The primary outcome includes pain intensity. It can be assessed by the visual analogue scale or other pain score tools.

The secondary outcomes comprise functional status, quality of life, psychological outcomes, as well as the adverse events. The functional status can be measured by the Roland--Morris Disability Questionnaire or other related tools. The quality of life, and psychological outcomes can be examined by the 36-Item Short Form Health Survey and Beck Depression Inventory, respectively, or any other associated scales.

2.2. Literature search
----------------------

We will search the databases of Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, PUBMED, Cumulative Index to Nursing and Allied Health Literature, China National Knowledge Infrastructure, Chinese Biomedical Literature Database, Chinese Scientific Journal Database, and Wanfang Data from inception to January 1, 2019 without language restrictions. Reference lists of included studies will also be checked to identify any potential eligible trials. The search strategy for CENTRAL is presented in Table [1](#T1){ref-type="table"}. The similar detailed strategies will be used for literature search from other electronic databases.

###### 

Search strategy applied in CENTRAL database.

![](medi-98-e14511-g001)

2.3. Study selection
--------------------

Two authors will independently check the titles, abstracts, and full texts, and will select all potential eligible studies against all inclusion and exclusion criteria. All disagreements will be settled down through discussion with a third author joined in. The study flow diagram is presented in Figure [1](#F1){ref-type="fig"}.

![Diagram flow of study selection.](medi-98-e14511-g002){#F1}

2.4. Data extraction and management
-----------------------------------

Data extraction will be independently performed by two authors using a predefined standardized data extraction sheet. The following information will be extracted: first author, published year, location, study design and methods, interventions, outcomes, and any other reporting information. A third author will be invited as an arbiter if divergences occur between two authors. We will contact the original authors to require the missing data if those data are not available. If those data are not obtainable, we will analyze the present available data.

2.5. Risk of bias assessment
----------------------------

Risk of bias assessment will be evaluated by using the criteria as described in details of the Cochrane Handbook of Systematic Review of Interventions. Two authors will independently evaluate each included study, with a third author acting as an arbiter through discussion if any differences regarding the risk of bias assessment arise.

2.6. Statistical analysis
-------------------------

### 2.6.1. Treatment effect measurement

We will express the treatment effects using risk ratio with 95% confidence intervals (CIs) for dichotomous data, and mean difference or standardized mean difference with 95% CIs for continuous data.

### 2.6.2. Assessment of heterogeneity

We will check the heterogeneity using the test of *I*^2^ and *χ*^2^. The heterogeneity is considered as acceptable if *I*^2^ ≤ 50%. Otherwise, significant heterogeneity is considered, and subgroup analysis should be conducted after the data pooled.

### 2.6.3. Data synthesis

Outcome data will be pooled by using fixed-effect model with acceptable heterogeneity. Otherwise, we will use random-effect model to pool the data, and we will also perform subgroup analysis. We will not consider pooling the data if the heterogeneity is still substantial after the subgroup analysis.

### 2.6.4. Subgroup analysis

We will conduct the subgroup analysis when the heterogeneity is not acceptable. It will be performed according to the different treatments, controls, outcome tools.

### 2.6.5. Sensitivity analysis

We will carry out the sensitivity analysis to check the robustness of the pooled results. It will be conducted depending on the different methodological qualities, and statistical models.

### 2.6.6. Publication bias

We will conduct the funnel plot to check the publication bias when more than 10 eligible trials are included. Meanwhile, we will also carry out Egger\'s and Begg\'s tests to check asymmetry of funnel plot.

3. Discussion
=============

To our best knowledge, this systematic review firstly explores the effectiveness and safety of EPSW for LBP. It will supply a detailed summary of the current evidence relevant of EPSW in pain relief, improving functional status, quality of life, as well as the psychological outcomes of patients with LBP. This evidence may be helpful to the clinical practice, patients, and health policy makers regarding the use of EPSW in the treatment of LBP.
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